Abcodia Ltd. is using blood samples that have been taken annually by the U.K. Collaborative Trial for Ovarian Cancer Screening to identify serum biomarkers that can detect breast, lung, pancreatic and colorectal tumors at least one year before symptomatic presentation.

Cancer biomarkers identified through comparisons of samples from diagnosed cancer patients and matched healthy controls may not be useful for widespread screening as they rely on threshold levels that may miss cancer in individuals with biomarkers that are rising but low, or falsely diagnose a healthy subject with naturally high levels.